Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.

Schnetzke U, Fischer M, Kuhn AK, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S.

J Cancer Res Clin Oncol. 2013 Apr;139(4):605-15. doi: 10.1007/s00432-012-1362-4.

PMID:
23263202
2.

The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.

Schnetzke U, Fischer M, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S.

Leuk Res. 2013 Nov;37(11):1557-64. doi: 10.1016/j.leukres.2013.08.004.

PMID:
23998902
3.

TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.

Jakus PB, Kalman N, Antus C, Radnai B, Tucsek Z, Gallyas F Jr, Sumegi B, Veres B.

J Nutr Biochem. 2013 May;24(5):819-23. doi: 10.1016/j.jnutbio.2012.04.017.

PMID:
22925919
4.

Ablation of Akt2 protects against lipopolysaccharide-induced cardiac dysfunction: role of Akt ubiquitination E3 ligase TRAF6.

Zhang Y, Xu X, Ceylan-Isik AF, Dong M, Pei Z, Li Y, Ren J.

J Mol Cell Cardiol. 2014 Sep;74:76-87. doi: 10.1016/j.yjmcc.2014.04.020.

5.

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.

Acta Pharmacol Sin. 2015 Mar;36(3):385-99. doi: 10.1038/aps.2014.142.

6.

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

Kim KT, Levis M, Small D.

Br J Haematol. 2006 Sep;134(5):500-9.

PMID:
16869825
7.

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, Kurosu T, Miura O.

Oncotarget. 2015 Apr 20;6(11):9189-205.

8.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

9.

TRAF6 promotes myogenic differentiation via the TAK1/p38 mitogen-activated protein kinase and Akt pathways.

Xiao F, Wang H, Fu X, Li Y, Wu Z.

PLoS One. 2012;7(4):e34081. doi: 10.1371/journal.pone.0034081.

10.

NFATc1 as a therapeutic target in FLT3-ITD-positive AML.

Metzelder SK, Michel C, von Bonin M, Rehberger M, Hessmann E, Inselmann S, Solovey M, Wang Y, Sohlbach K, Brendel C, Stiewe T, Charles J, Ten Haaf A, Ellenrieder V, Neubauer A, Gattenlöhner S, Bornhäuser M, Burchert A.

Leukemia. 2015 Jul;29(7):1470-7. doi: 10.1038/leu.2015.95.

PMID:
25976987
11.

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.

Leuk Res. 2008 Sep;32(9):1382-92. doi: 10.1016/j.leukres.2008.02.018.

PMID:
18394702
12.

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.

Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055.

13.

BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.

Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW, Villunger A, Jönsson JI.

Blood. 2009 Mar 5;113(10):2302-11. doi: 10.1182/blood-2008-07-167023.

14.
15.

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.

Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM.

Leukemia. 2008 Jan;22(1):147-60.

PMID:
17928881
16.

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.

Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M.

Leuk Res. 2012 Feb;36(2):224-31. doi: 10.1016/j.leukres.2011.07.011.

17.
18.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017.

PMID:
20380868
19.

[COX-2 inhibitor celecoxib can suppress the proliferation of FLT3-ITD positive acute myeloid leukemia cells with prominent down regulation of MEK/MCL-1 expression in vitro].

Du LX, Jia YQ, Meng WT, Shi FF, Zhong XS, Ma LL, Yuan J, Zeng JS.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1157-61. doi: 10.7534/j.issn.1009-2137.2013.04.014. Chinese.

PMID:
24156425
20.

Novel aminobenzyl-acetamidine derivative modulate the differential regulation of NOSs in LPS induced inflammatory response: role of PI3K/Akt pathway.

Patruno A, Franceschelli S, Pesce M, Maccallini C, Fantacuzzi M, Speranza L, Ferrone A, De Lutiis MA, Ricciotti E, Amoroso R, Felaco M.

Biochim Biophys Acta. 2012 Dec;1820(12):2095-104. doi: 10.1016/j.bbagen.2012.08.014.

PMID:
22951221

Supplemental Content

Support Center